PatientsVille.com Logo


Artemether Medical Research Studies

Up-to-date List of Artemether Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Artemether Medical Research Studies

Rank Status Study
1 Recruiting Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria
Condition: Malaria
Intervention: Other: Artemether-lumefantrine
Outcome Measures: Effectiveness: Resolution of clinical signs and symptoms after Artemether-lumefantrine treatment start;   Adverse event, serious adverse event after Artemether-lumefantrine treatment start;   Pregnancies after Artemether-lumefantrine treatment start
2 Recruiting Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day
Condition: Plasmodium Falciparum Infection
Interventions: Drug: Artemether-lumefantrine 3 days;   Drug: Artemether-lumefantrine 5 days
Outcome Measures: proportion of patients with detectable parasitaemia;   Parasitaemia clearance time;   Gametocyte carriage rates;   Artemether-lumefantrine tolerability;   Comparison of effectiveness;   concentrations of lumefantrine;   Haematological recovery rate;   Incidence of vivax malaria relapses
3 Not yet recruiting Efficacy and Safety of a Single Low-dose Primaquine for the Clearance of Gametocytes
Condition: Plasmodium Falciparum
Interventions: Drug: Primaquine (For Artemether-lumefantrine+primaquine arm);   Drug: Placebo (For Artemether-lumefantrine arm)
Outcome Measures: Number of days per treatment arm for gametocytes to become undetectable using Quantitative nucleic acid sequence based assay (QT-NASBA).;   Mean maximal fall in hemoglobin (g/dl) from enrolment to day 28 of follow-up defined as mean greatest negative difference in hemoglobin per treatment arm.
4 Recruiting Ethiopia Antimalarial in Vivo Efficacy Study 2012
Condition: Plasmodium Vivax Infection
Interventions: Drug: Artemether-lumefantrine combination;   Drug: Primaquine;   Drug: Chloroquine
Outcome Measures: P. vivax treatment failures in the 4 weeks following treatment with AL compared to AL+PQ;   P. vivax treatment failures in the 4 weeks following treatment with CQ compared to CQ+PQ;   Number of episodes of P. vivax parasitemia over one year following initial effective therapy against P. vivax (i.e. parasite clearance);   P. vivax treatment failures in the 6 weeks following treatment
5 Not yet recruiting P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine
Condition: Uncomplicated Knowlesi Malaria
Interventions: Drug: Artemether-lumefantrine combination;   Drug: Chloroquine
Outcome Measures: Parasite clearance;   Rates of recurrent infection / treatment failure at day 42.;   Occurrence of anaemia at day 28 when using AL vs. CQ.;   P. knowlesi and gametocyte carriage throughout follow up when using AL vs. CQ.;   Frequency of complications throughout follow up when using AL vs. CQ.
6 Unknown  Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children
Condition: Uncomplicated Malaria
Interventions: Drug: Artemether-lumefantrine;   Drug: Oral quinine
Outcome Measures: 1. PCR adjusted parasitological cure rate on day 28. 2. Clinical cure rates on day 28.;   1. Fever clearance time assessed by self report. 2. Hemoglobin changes on day 0, 7, 14 and 28. 3. Safety profiles. 4. Adherence: measured by patient report and pill count on day 3 for the Artemether-Lumefantrine group and day 7 for the quinine group.
7 Not yet recruiting Efficacy and Bio-availability of Artemether-Lumefantrine in Severely Malnourished Children
Conditions: Malaria;   Severe Acute Malnutrition
Intervention: Drug: Artemether-lumefantrine fixed combination
Outcome Measures: Proportion of adequate clinical and parasitological response after PCR correction;   Percentage of adequate clinical and parasitological response corrected by PCR;   Proportion of treatment failures by types (Early Treatment Failure, Late Clinical Failure, Late Parasitological Failure);   Proportion of reinfection and recrudescence;   Bio-availability of lumefantrine;   Type and frequency of adverse events
8 Recruiting Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics
Condition: Malaria, Falciparum
Intervention: Dietary Supplement: Food
Outcome Measures: Pharmacokinetic (PK) exposure parameters of lumefantrine;   Relative Oral Bioavailability of lumefantrine
9 Recruiting Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg
Condition: Acute Uncomplicated Falciparum Malaria
Interventions: Drug: COA566;   Drug: Artemether-lumefantrine dispersible tablet
Outcome Measures: Polymerase Chain Reaction (PCR) corrected 28 day parasitological cure rate;   Polymerase Chain Reaction (PCR) corrected parasitological cure rate at day 14;   Polymerase Chain Reaction (PCR) corrected parasitological cure rate at day 42;   Parasitological uncorrected cure rate at day 3;   Parasitological uncorrected cure rate at day 7;   Parasitological uncorrected cure rate at day 14;   Parasitological uncorrected cure rate at day 28;   Parasitological uncorrected cure rate at day 42;   Parasite reduction at 24 hours after treatment initiation;   Number of patients with parasitaemia at 72 hours after treatment initiation greater than or equal to 25 percent of count at baseline;   Number of patients with parasitaemia at 48 hours after treatment initiation greater than at baseline;   Time to parasite clearance (PCT);   Time to fever clearance (FCT);   Time to gametocyte clearance (GCT);   Gametocyte carriage over time;   Incidence of serious adverse events (SAEs);   Incidence of adverse events (AEs);   Biochemical and haematological changes
10 Recruiting Low Dose Primaquine for Clearance of Gametocytes
Conditions: Malaria;   Asymptomatic Malaria;   Plasmodium Falciparum
Interventions: Drug: Artemether-lumefantrine combination;   Drug: Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine;   Drug: Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine
Outcome Measures: Gametocyte carriage;   Transmission to Anopheles gambiae mosquitoes;   Haematological recovery
11 Recruiting Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A
Condition: Malaria
Interventions: Drug: Artemether-lumefantrine;   Drug: Dihydroartemisinin-piperaquine
Outcome Measures: Adequate clinical and parasitological response rate;   the safety of AL and DP
12 Unknown  Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan
Condition: Malaria
Interventions: Drug: Dihydroartemisinin- piperaquine;   Drug: Artemether- lumefantrine
Outcome Measure: comparing the cure rate between the two drugs
13 Recruiting Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon
Condition: Malaria
Interventions: Drug: Artesunate-Amodiaquine;   Drug: Dihydroartemisinine-Piperaquine;   Drug: Artemether-lumefantrine combination
Outcome Measures: Clinical Efficacy;   Safety
14 Unknown  Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana
Conditions: Malaria;   Schistosomiasis;   Helminthiasis;   Anemia;   Change in Sustained Attention
Interventions: Drug: Artemether-lumefantrine combination plus albendazole;   Drug: Artemether-lumefantrine plus Praziquantel plus Albendazole;   Drug: Albendazole plus Praziquantel
Outcome Measures: Prevalence and density of malaria parasites, determined by microscopy, as a measure of efficacy;   Number of participants with adverse events as a measure of safety and tolerability;   Number of schoolchildren with sustained attention and recall as a measure of efficacy;   Proportion of schoolchildren with anemia as a measure of safety and tolerability;   Prevalence and intensity of urinary schistosomiasis as a measure of efficacy;   Prevalence and density of malaria parasites by microscopy as a measure of efficacy;   Prevalence and intensity of intestinal schistosomiasis among schoolchildren as a measure of efficacy
15 Recruiting Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger
Condition: Malaria
Interventions: Drug: Artesunate-amodiaquine;   Drug: Dihydroartemisinin-piperaquine;   Drug: Artemether-lumefantrine
Outcome Measures: Adequate clinical and parasitological response;   Early treatment failure;   Late clinical failure;   Late Parasitological Failure
16 Recruiting Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy
Condition: Malaria
Interventions: Drug: dihydroartemisinin-piperaquine;   Drug: Artesunate-mefloquine;   Drug: arthemeter-lumefantrin
Outcome Measures: Cure rate defined as clearance of asexual parasites without recurrence within the period between treatment and delivery or a 63 day period;   Number of adverse events;   Biochemical and haematological changes;   Kinetic parameters of artesunate, mefloquine, piperaquine and lumefantrine;   Anaemia;   Gametocyte carriage;   Changes in the Reticulocyte counts;   Malaria infection rate at delivery and placental parasitaemia;   Pregnancy outcomes (abortions, low birth weight, premature birth, congenital abnormality, stillbirths, neonatal and infant mortality);   Infant growth and development at 1 year of life
17 Recruiting Adherence to Antimalarial Drugs in Sierra Leone
Condition: Malaria
Interventions: Drug: amodiaquine-artesunate (AQAS) co-formulated;   Drug: Artemether-lumefantrine combination (AL)
Outcome Measure: Adherence
18 Recruiting Evaluation of the Riamet® Versus Malarone® in the Treatment of Uncomplicated Malaria
Condition: Malaria
Interventions: Drug: Malarone (atovaquone + proguanil combination);   Drug: RIAMET (Artemether + LUMEFANTRIN combination)
Outcome Measures: Number of cases where a second line treatment is used for either intolerance or lack of effectiveness;   Parasitological cure rate;   Fever clearance;   Digestive tolerance;   Number of relapses
19 Unknown  Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period
Condition: Malaria
Intervention: Drug: Artemether-lumefantrine combination
Outcome Measures: Prevalence of ototoxicity at 18 months and 36 months of enrolment.;   Incidence of clinical malaria during 18 months and 36 months of follow-up
20 Recruiting The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy
Condition: Malaria Transmission
Interventions: Drug: Artemether Lumefantrine;   Drug: Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0;   Drug: Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2
Outcome Measures: Gametocyte prevalence and density by microscopy and QT-NASBA;   Haemoglobin level

These studies may lead to new treatments and are adding insight into Artemether etiology and treatment.

A major focus of Artemether research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.

Discuss Artemether